DNLI: Avlayah's launch validates a platform poised for global expansion and broad neurotherapeutic impact
Competition, especially from China, is accelerating innovation in blood-brain barrier therapies. Avlayah's launch validates the platform, with rapid U.S. uptake and global expansion planned. The pipeline includes promising programs in rare diseases and neurodegeneration, with AI and in-house manufa…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.